vesigenurtucel-L (HS-410) / Scorpius Holdings - LARVOL DELTA

Sodium Selenate, Potassium Hydroxy-Selenide, Acetylselenide and Their Effect on Antioxidant Metabolism and Plant Nutrition and Yield in Sorghum Genotypes. (PubMed, Foods) - "In sum, biofortification with selenium led to an overall yield increase of sorghum plants and supplementation with selenium through sodium selenate was more efficient than organoselenium compounds, yet acetylselenide had a positive effect on the antioxidant system. Sorghum can be effectively biofortified through the foliar application of sodium selenate; however, studying the interaction between organic and inorganic Se compounds in plants is necessary."

Journal • CAT

Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC). (ASCO-GU 2017) - P1/2; "Vesigenurtacel-L is well-tolerated, and immunologic responses consistent with vaccine mechanism of action may correlate with efficacy and suggest future biomarkers. Vesigenurtacel-L warrants further investigation as a potential treatment for NMIBC."

Biomarker • P2 data • Bladder Cancer • Prostate Cancer

Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC). (ASCO 2017) - P1/2; "Vesigenurtacel-L is well-tolerated, and immunologic responses consistent with vaccine mechanism of action may correlate with efficacy and suggest future biomarkers. Vesigenurtacel-L warrants further investigation as a potential treatment for NMIBC."

Biomarker • Combination therapy • P2 data • Biosimilar • Bladder Cancer

Biological and trophic consequences of genetic introgression between endemic and invasive Barbus fishes. (PubMed, Biol Invasions) - "These results attest that the genetic introgression of an invasive congener with native species can result in substantial ecological consequences, including the potential for cascading effects. The online version contains supplementary material available at 10.1007/s10530-021-02577-6."

Journal

Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle invasive bladder cancer. (PubMed, Cancer Epidemiol Biomarkers Prev) - "This study serves as a hypothesis generating report for future studies to evaluate the role of urine cytokines as a predictive biomarker of response to immune treatments."

Biomarker • Clinical • Journal • Bladder Cancer • Genito-urinary Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • Urothelial Cancer

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT (clinicaltrials.gov) - P1/2; N=104; Terminated; Sponsor: Heat Biologics; Completed ➔ Terminated; Inability to accrue due to changing treatment landscape (PD-1 approvals)

Clinical • IO Biomarker • Trial termination • CD8 • TIL

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT (clinicaltrials.gov) - P1/2; N=93; Recruiting; Sponsor: Heat Biologics

Clinical • IO Biomarker • New P1/2 trial

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT (clinicaltrials.gov) - P1/2; N=104; Completed; Sponsor: Heat Biologics; Active, not recruiting ➔ Completed; Trial completion date: Apr 2020 ➔ Apr 2018; Trial primary completion date: Apr 2017 ➔ Dec 2017

Clinical • IO Biomarker • Trial completion • Trial completion date • Trial primary completion date